LG Chem Holds Symposium on Hyperphosphatemia Treatment "Nepoxil"

On September 10, LG Chem announced that it had held the “Guide Symposium” to share the latest academic information on Nepoxil, its treatment for hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis.

LG Chem is holding a symposium on Nepoxil, a treatment for hyperphosphatemia. LG Chem

Nepoxil is an iron-based, non-calcium phosphate binder that effectively reduces phosphate levels while simultaneously providing additional iron supplementation.

During the symposium, domestic nephrology specialists actively discussed the main revisions to the “2025 KDIGO (Kidney Disease: Improving Global Outcomes) Anemia Treatment Guidelines” currently under review, as well as strategies for applying these changes in clinical practice. Effective hyperphosphatemia treatment solutions based on Nepoxil’s clinical results were also presented.

KDIGO announced that the monitoring interval for iron parameters in hemodialysis patients will be revised from every three months to every month. It also strongly recommended the use of intravenous (IV) iron formulations for patients with stage 5 chronic kidney disease undergoing hemodialysis.

On this day, LG Chem emphasized that Nepoxil, an iron-based, non-calcium phosphate binder, aligns with the newly revised treatment guidelines. The company highlighted Nepoxil as an ideal treatment for hyperphosphatemia, offering not only effective serum phosphate control but also the added benefit of iron supplementation.

Additionally, LG Chem shared results from a phase 3 clinical trial of Nepoxil conducted in Japan, which showed that Nepoxil achieved similar efficacy to the comparator drug containing sevelamer at a lower dose. By week 12 of administration, serum phosphate levels had reached below the treatment target of 5.5 mg/dL.

The company further analyzed that the significant increase in iron parameters, as an additional effect, led to a reduction in the use of iron supplements and erythropoiesis-stimulating agents. Ultimately, Nepoxil may have a positive impact on reducing the economic burden for hemodialysis patients.

In addition to Nepoxil, academic presentations were also held on Nesp, a long-acting erythropoiesis-stimulating agent, and Orkedia, a treatment for secondary hyperparathyroidism.

An LG Chem marketing representative stated, “Nepoxil not only provides phosphate control comparable to existing treatments but also offers advantages for anemia treatment through its additional iron supplementation effect. We will continue to develop and provide effective and accessible treatment options to improve the quality of life for domestic patients with chronic kidney disease.”

This content was produced with the assistance of AI translation services.